Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KRN125 vs KRN8601 for hematopoietic stem cell mobilization in multiple myeloma and malignant lymphoma
jRCT2011210029Completed
- Sponsor
- Kyowa Kirin
- Start
- Sep 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised trial of pegfilgrastim in multiple myeloma (MM) and lymphosarcoma (2 arms), sponsored by Kyowa Kirin. Primary endpoint: Primary: CD34+ yield in multiple myeloma. Started Sep 2021; status: completed.
02
Drugs
pegfilgrastim
03
Conditions
multiple myeloma (MM)lymphosarcoma
Beyond the preview
Go deeper on jRCT2011210029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011210029.